Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
The Washington Post on MSN6d
She was diagnosed with Parkinson’s at 27. These were her warning signs.People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Registration is open for free 'Living Your Best Life with Parkinson's Disease' event, hosted by Tallahassee's Sweat Therapy ...
The Oklahoma Medical Research Foundation has received a $3 million grant to study Parkinson's disease, potentially leading to ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
She was happily married, pregnant with her first child and had recently completed her residency in family medicine. Soon ...
1don MSN
The Parkinson’s Foundation estimates that 15,000 people here in Wisconsin have Parkinson’s disease, and that number is only ...
Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-s ...
Gain Therapeutics, Inc. has announced significant developments in its clinical program for GT-02287, a potential disease-modifying therapy for Parkinson's disease, which is set to enter a Phase 1b ...
FDA Approves Supernus Pharmaceuticals’ Onapgo for Managing Motor Fluctuations in Parkinson Disease
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
Nicole LaBolle initially dismissed her shaking as something fairly common before facing a Parkinson's diagnosis at 28 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback